New Zealand - English - Medsafe (Medicines Safety Authority)

takeda new zealand limited - octocog alfa 500 [iu] - injection with diluent - 500 iu - active: octocog alfa 500 [iu] excipient: albumin calcium chloride dihydrate histidine hydrochloric acid macrogol 3350 sodium chloride sodium hydroxide water for injection - in haemophilia a (classical haemophilia) for the prevention and control of haemorrhagic episodes. · in the perioperative management of patients with haemophilia a (classical haemophilia).

Australia - English - Department of Health (Therapeutic Goods Administration)

bayer australia ltd - octocog alfa, quantity: 500 iu - liquid, multipurpose - excipient ingredients: water for injections - treatment and prophylaxis of bleeding in patients with haemophilia a (congenital factor viii deficiency). kovaltry can be used for all age groups. (see clinical trials section). kovaltry does not contain von willebrand factor and is not indicated in von willebrand disease.

Australia - English - Department of Health (Therapeutic Goods Administration)

csl behring australia pty ltd - lonoctocog alfa, quantity: 500 iu - solution - excipient ingredients: - afstyla is indicated in adult and paediatric patients with haemophilia a (congenital fviii deficiency) for: - control and prevention of bleeding episodes - routine prophylaxis to prevent or reduce the frequency of bleeding episodes - perioperative management (surgical prophylaxis) afstyla is not indicated for the treatment of von willebrand disease.

Australia - English - Department of Health (Therapeutic Goods Administration)

csl behring australia pty ltd - lonoctocog alfa, quantity: 2500 iu - solution - excipient ingredients: - afstyla is indicated in adult and paediatric patients with haemophilia a (congenital fviii deficiency) for: - control and prevention of bleeding episodes - routine prophylaxis to prevent or reduce the frequency of bleeding episodes - perioperative management (surgical prophylaxis) afstyla is not indicated for the treatment of von willebrand disease.

Australia - English - Department of Health (Therapeutic Goods Administration)

csl behring australia pty ltd - lonoctocog alfa, quantity: 1500 iu - solution - excipient ingredients: - afstyla is indicated in adult and paediatric patients with haemophilia a (congenital fviii deficiency) for: - control and prevention of bleeding episodes - routine prophylaxis to prevent or reduce the frequency of bleeding episodes - perioperative management (surgical prophylaxis) afstyla is not indicated for the treatment of von willebrand disease.

Singapore - English - HSA (Health Sciences Authority)

pfizer private limited - moroctocog alfa (af-cc) - injection, powder, for solution - 500iu/vial - moroctocog alfa (af-cc) 500iu/vial

Malta - English - Medicines Authority

baxter healthcare limited - octocog alfa 500 iu - powder and solvent for solution for injection

Israel - English - Ministry of Health

novo nordisk ltd, israel - turoctocog alfa - powder and solvent for solution for injection - turoctocog alfa 1500 iu / 4 ml - coagulation factor viii - treatment and prophylaxis of bleeding in patients with haemophilia a (congenital factor viii deficiency).novoeight can be used for all age groups.

Israel - English - Ministry of Health

pfizer pharmaceuticals israel ltd - moroctocog alfa - lyophylized powder and solvent for solution for injection - moroctocog alfa 500 iu/vial - coagulation factor viii - coagulation factor viii - treatment and prophylaxis of bleeding in patients with haemophilia a (congenital factor viii deficiency)

Australia - English - Department of Health (Therapeutic Goods Administration)

csl behring australia pty ltd - lonoctocog alfa, quantity: 3000 iu - solution - excipient ingredients: - afstyla is indicated in adult and paediatric patients with haemophilia a (congenital fviii deficiency) for: - control and prevention of bleeding episodes - routine prophylaxis to prevent or reduce the frequency of bleeding episodes - perioperative management (surgical prophylaxis) afstyla is not indicated for the treatment of von willebrand disease.